Press Releases Archives | Page 100 of 118

Qrons Appoints Veteran U.S. Based Biotech Executive Dr. John N. Bonfiglio to Lead IND and Capital Markets Related Activities

June 27, 2019 By Cade Hildreth, Founder & President Leave a Comment

New York, NY, June 27, 2019 — Qrons Inc. (OTC: QRON), an emerging biotechnology company developing advanced stem cell-synthetic hydrogel-based solutions for the treatment of traumatic brain injuries (“TBIs”), including concussions and penetrating injuries, announced today the appointment of John N. Bonfiglio, PhD, MBA as its Chief Operating Officer. Qrons Inc. (OTC: QRON)

Dr. Bonfiglio’s primary responsibility will be to oversee all investigational new drug (“IND”) activities in the United States in coordination with Qrons’ Israeli-based scientific team. [Read more…]

ExCellThera enters into a manufacturing and collaboration agreement with New York Blood Center

June 4, 2019 By Cade Hildreth, Founder & President Leave a Comment

MONTREAL, MAY 7, 2019 – ExCellThera Inc., an advanced clinical stage biotechnology company delivering molecules and bioengineering solutions to expand stem and immune cells for therapeutic use, announced today that it has entered into a manufacturing and collaboration agreement with Comprehensive Cell Solutions (CCS), a division of New York Blood Center (NYBC) for the clinical grade production of ExCellThera’s lead cell therapy product, ECT-001. [Read more…]

ElevateBio to Create a Portfolio of Innovative Cell and Gene Therapy Companies

May 26, 2019 By Cade Hildreth, Founder & President Leave a Comment

– ElevateBio to leverage its fully integrated, company building bench-to-bedside capabilities exclusively focused on cell and gene therapies

– ElevateBio’s BaseCamp, an R&D, process development and cGMP manufacturing subsidiary, provides cell and gene expertise for all ElevateBio portfolio companies and selected strategic partners

– $150 MM Series A financing co-led by UBS Oncology Impact Fund Managed by MPM Capital and F2 Ventures joined by EcoR1 Capital, Redmile Group, and Samsara BioCapital

CAMBRIDGE, Mass. — ElevateBio, a Cambridge-based biotechnology holding company, today announced operations to create and build a broad portfolio of cell and gene therapy companies through partnerships with leading academic researchers, medical centers and entrepreneurs. [Read more…]

ExCellThera’s Cell Expansion Technology, ECT-001, Receives FDA RMAT Designation

April 29, 2019 By Cade Hildreth, Founder & President Leave a Comment

MONTREAL, April 23, 2019 — ExCellThera Inc., an advanced clinical stage biotechnology company delivering molecules and bioengineering solutions to expand stem and immune cells for therapeutic use, announced today that the U.S. Food and Drug Administration (FDA) has granted regenerative medicine advanced therapy (RMAT) designation to its lead technology, ECT-001, in the treatment of hematologic malignancies. The RMAT designation is based on strong data from Phase I/II clinical trials using ECT-001 to expand stem and immune cells for the treatment of blood cancers. [Read more…]

Talaris Therapeutics Receives RMAT, Raises $100M, Announces Promising Phase II Data for Kidney Transplant

April 25, 2019 By Cade Hildreth, Founder & President Leave a Comment

Talaris Therapeutics’ RMAT and Promising Phase 2 Data of Cell Therapy for Living Donor Kidney Transplant Recipients

BOSTON & LOUISVILLE, Ky.–Apr 18, 2019–Talaris Therapeutics, Inc., formerly Regenerex, a privately held biotechnology company developing transformative cell therapies that have the potential to eliminate the burden of chronic immunosuppression for organ transplant recipients, today announced full results of its Phase 2 trial of FCR001 in living donor kidney transplant (LDKT) recipients. The therapy’s strong durability of benefit and safety profile support the initiation of a Phase 3 clinical trial in LDKT later this year.

[Read more…]